Cyclacel Pharmaceuticals (CYCC) Receiving Somewhat Positive News Coverage, Report Shows

Headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have been trending somewhat positive on Wednesday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.7801807128744 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) traded down $0.05 during trading on Wednesday, reaching $1.71. 260,700 shares of the company were exchanged, compared to its average volume of 168,450. Cyclacel Pharmaceuticals has a 1 year low of $1.50 and a 1 year high of $10.90. The firm has a market cap of $20.48, a price-to-earnings ratio of -0.70 and a beta of 3.74.

ILLEGAL ACTIVITY NOTICE: “Cyclacel Pharmaceuticals (CYCC) Receiving Somewhat Positive News Coverage, Report Shows” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/10/cyclacel-pharmaceuticals-cycc-receiving-somewhat-positive-news-coverage-report-shows.html.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.

Insider Buying and Selling by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit